Pluripotent Stem Cell-Derived Hepatocyte-like Cells: A Tool to Study Infectious Disease
- PMID: 29910973
- PMCID: PMC5998817
- DOI: 10.1007/s40139-016-0113-7
Pluripotent Stem Cell-Derived Hepatocyte-like Cells: A Tool to Study Infectious Disease
Abstract
Purpose of review: Liver disease is an important clinical and global problem and is the 16th leading cause of death worldwide and responsible for 1 million deaths worldwide each year. Infectious disease is a major cause of liver disease specifically and overall is even a greater cause of patient morbidity and mortality. Tools to study human liver disease and infectious disease have been lacking which has significantly hampered the study of liver disease generally and hepatotropic pathogens more specifically. Historically, hepatoma cell lines have been used for in vitro cell culture models to study infectious disease. Significant differences between human hepatoma cell lines and the human hepatocyte has hampered our understanding of hepatocyte pathogen infection and hepatocyte--pathogen interactions.
Recent findings: Despite these limitations, great progress was made in the understanding of specific aspects of the life cycle of the canonical hepatocyte viral pathogen, Hepatitis C Virus. Over time various specific drugs targeting various proteins of the HCV virion or aspects of the HCV viral life cycle have been created that enable almost complete elimination of the virus in vitro and clinically. These drugs, direct-acting antivirals have enabled achieving sustained virologic response in over 90-95 percent of patients.
Summary: Despite the development of direct-acting antivirals and the extreme success in achieving sustained virologic response, there has only been limited success elucidating host-pathogen interactions largely due to the poor nature of the hepatoma platform. Alternative approaches are needed. Pluripotent stem cells are renewable, can be derived from a single donor and can be efficiently and reproducibly differentiated towards many cell types including ectodermal-, endodermal-, and mesodermal-derived lineages. The development of pluripotent stem cell-derived hepatocyte-like cells (iHLCS) changes the paradigm as robust cells with the phenotype and function of hepatocytes can be readily created on demand with a variety of genetic background or alterations. iHLCs are readily used as models to study human drug metabolism, human liver disease, and human hepatotropic infectious disease. In this review, we discuss the biology of the HCV virus, the use of iHLCs as models to study human liver disease, and review the current work on using iHLCs to study HCV infection.
Keywords: Disease model; Hepatitis C virus; Hepatotropic pathogen; Human hepatocyte; Induced pluripotent stem Cells; Pluripotent stem cells.
Similar articles
-
Pluripotent stem cell-derived hepatocyte-like cells.Biotechnol Adv. 2014 Mar-Apr;32(2):504-13. doi: 10.1016/j.biotechadv.2014.01.003. Epub 2014 Jan 16. Biotechnol Adv. 2014. PMID: 24440487 Free PMC article. Review.
-
Functional innate immunity restricts Hepatitis C Virus infection in induced pluripotent stem cell-derived hepatocytes.Sci Rep. 2018 Mar 1;8(1):3893. doi: 10.1038/s41598-018-22243-7. Sci Rep. 2018. PMID: 29497123 Free PMC article.
-
A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host.Virol J. 2016 Apr 5;13:59. doi: 10.1186/s12985-016-0519-1. Virol J. 2016. PMID: 27044429 Free PMC article.
-
Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus.J Hepatol. 2012 Aug;57(2):246-51. doi: 10.1016/j.jhep.2012.03.030. Epub 2012 Apr 17. J Hepatol. 2012. PMID: 22521345
-
The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.J Hepatol. 2016 Oct;65(1 Suppl):S2-S21. doi: 10.1016/j.jhep.2016.07.035. J Hepatol. 2016. PMID: 27641985 Review.
Cited by
-
Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery.Philos Trans R Soc Lond B Biol Sci. 2018 Jul 5;373(1750):20170228. doi: 10.1098/rstb.2017.0228. Philos Trans R Soc Lond B Biol Sci. 2018. PMID: 29786562 Free PMC article. Review.
-
Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development.Med Microbiol Immunol. 2019 Feb;208(1):3-24. doi: 10.1007/s00430-018-0566-x. Epub 2018 Oct 8. Med Microbiol Immunol. 2019. PMID: 30298360 Review.
-
Cell and Tissue Therapy for the Treatment of Chronic Liver Disease.Annu Rev Biomed Eng. 2021 Jul 13;23:517-546. doi: 10.1146/annurev-bioeng-112619-044026. Epub 2021 May 11. Annu Rev Biomed Eng. 2021. PMID: 33974812 Free PMC article. Review.
-
Modeling Hepatotropic Viral Infections: Cells vs. Animals.Cells. 2021 Jul 8;10(7):1726. doi: 10.3390/cells10071726. Cells. 2021. PMID: 34359899 Free PMC article. Review.
-
iPSC-Derived Hepatocytes as a Platform for Disease Modeling and Drug Discovery.Front Med (Lausanne). 2019 Nov 15;6:265. doi: 10.3389/fmed.2019.00265. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31803747 Free PMC article. Review.
References
-
- Li K, Chen Z, Kato N, Gale M, Jr, Lemon SM. Distinct poly(I–C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem. 2005;280(17):16739–16747. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials